You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 7,745,174

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,745,174

Title:	Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor
Abstract:	The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.
Inventor(s):	Kim; Jong-Mook (Seoul, KR), Hahn; Woong (Goyang, KR), Park; Eun-Jin (Seoul, KR)
Assignee:	Viromed Co., Ltd. (Seoul, KR)
Application Number:	12/650,860
Patent Claims:	1. A method for co-expressing two heterotypes of Hepatocyte Growth Factor (HGF) comprising transforming or transfecting to a cell a DNA construct comprising: (a) a promoter, (b) a first cDNA which has the same sequence as exons 1-4 of the human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA, (c) a polynucleotide that has the same sequence as intron 4 of the HGF gene or a functional fragment thereof, and (d) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA; wherein (c) is located between (b) and (d); and the HGF construct simultaneously encodes two heterotypes of human HGF. 2. The method of claim 1, wherein said intron has the same sequence as a fragment of intron 4 of the HGF gene. 3. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 19. 4. The method of claim 3, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 19. 5. The method of claim 4, wherein the construct comprises the sequence of SEQ ID NO: 19. 6. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 20. 7. The method of claim 6, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 20. 8. The method of claim 7, wherein the construct comprises the sequence of SEQ ID NO: 20. 9. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 21. 10. The method of claim 9, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 21. 11. The method of claim 10, wherein the construct comprises the sequence of SEQ ID NO: 21. 12. The method of claim 1, wherein the one intron has the same sequence as the full intron 4 of the HGF gene. 13. The method of claim 1, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 2. 14. The method of claim 13, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 2. 15. The method of claim 14, wherein the construct comprises the sequence of SEQ ID NO: 2. 16. The method of claim 1, wherein the construct further comprises a terminator sequence, a self-replication sequence, or a secretory signal. 17. The method of claim 1, wherein the expression efficiency of the construct is higher than the expression efficiency of HGF cDNA or deleted variant HGF (dHGF) cDNA. 18. The method of claim 1, wherein the expression level of the construct is about 20- to 100-fold higher than the expression level of the HGF cDNA or dHGF cDNA. 19. The method of claim 1, wherein the cell is a mammalian cell, a bacterial cell or a yeast cell. 20. The method of claim 19, wherein the cell is a mammalian cell. 21. The method of claim 20, wherein the transformation of said mammalian cell is in vivo.

Details for Patent 7,745,174

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2022-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2022-03-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2022-03-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.